Noxopharm Limited (NOX:ASX)
Noxopharm Limited is an Australia-based clinical-stage drug development company. The Company is focused on the treatment of cancer and cytokine release syndrome or septic shock. The Company is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The Company's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The Company's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).